Selective Inhibition of Bruton's Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors
通过设计的共价配体选择性抑制布鲁顿酪氨酸激酶，与临床使用的抑制剂相比，对血癌具有更强的治疗效果
期刊:ACS Pharmacology & Translational Science
影响因子:4.9
doi:10.1021/acsptsci.2c00163
Bárbara B Sousa, Cátia Rebelo de Almeida, Ana F Barahona, Raquel Lopes, Ana Martins-Logrado, Marco Cavaco, Vera Neves, Luís A R Carvalho, Carlos Labão-Almeida, Ana R Coelho, Marta Leal Bento, Ricardo M R M Lopes, Bruno L Oliveira, Miguel A R B Castanho, Peter Neumeister, Alexander Deutsch, Gregory I
